Metabolic studies of 3 H-orphenadrine citrate in the rat, dog and rhesus monkey. - Suppr | 超能文献

Metabolic studies of 3 H-orphenadrine citrate in the rat, dog and rhesus monkey.

作者信息

Ellison T

出版信息

Arch Int Pharmacodyn Ther. 1972 Feb;195(2):213-30.

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Metabolic studies of 3 H-orphenadrine citrate in the rat, dog and rhesus monkey.

Arch Int Pharmacodyn Ther. 1972 Feb;195(2):213-30.

2

Physiological disposition and metabolism of cyclobenzaprine in the rat, dog, rhesus monkey, and man.环苯扎林在大鼠、狗、恒河猴和人体内的生理处置与代谢

Drug Metab Dispos. 1978 Nov-Dec;6(6):659-72.

3

Pharmacokinetics of mepindolol sulfate in the rat, dog, and rhesus monkey. Studies on species differences.硫酸美吲哚洛尔在大鼠、犬和恒河猴体内的药代动力学。种属差异研究。

Drug Metab Dispos. 1983 Mar-Apr;11(2):91-6.

4

Pharmacokinetics of ciprofloxacin. 1st communication: absorption, concentrations in plasma, metabolism and excretion after a single administration of [14C]ciprofloxacin in albino rats and rhesus monkeys.环丙沙星的药代动力学。首次通讯：白化大鼠和恒河猴单次给予[14C]环丙沙星后的吸收、血浆浓度、代谢及排泄情况

Arzneimittelforschung. 1986 Oct;36(10):1496-502.

5

Metabolism of disodium ethane-1-hydroxy-1,1-diphosphonate (disodium etidronate) in the rat, rabbit, dog and monkey.大鼠、兔、狗和猴体内1-羟基-1,1-二膦酸乙烷二钠（依替膦酸二钠）的代谢

Toxicol Appl Pharmacol. 1972 Apr;21(4):503-15. doi: 10.1016/0041-008x(72)90007-5.

6

Distribution of tritium-labelled tofenacine hydrochloride in the pregnant mouse.

Eur J Pharmacol. 1969 Oct;8(1):119-26. doi: 10.1016/0014-2999(69)90137-x.

7

Metabolism of beclomethasone dipropionate by animals and man.

Postgrad Med J. 1975;51 Suppl 4:11-20.

8

Pharmacokinetics and metabolism of cefazedone in Wistar rat, beagle dog and rhesus monkey.头孢唑酮在Wistar大鼠、比格犬和恒河猴体内的药代动力学与代谢

Arzneimittelforschung. 1979;29(2a):404-11.

9

The synthesis and metabolic fate of 14 C-viminol, a new analgesic, in the rat and the dog.

Arzneimittelforschung. 1973 May;23(5):708-12.

10

[Tissue glycoproteins].[组织糖蛋白]

Stud Cercet Med Interna. 1968;9(1):13-23.

引用本文的文献

1

Anticholinergic antiparkinson drug orphenadrine inhibits HERG channels: block attenuation by mutations of the pore residues Y652 or F656.抗胆碱能抗帕金森病药物奥芬那君抑制人类ether-a-go-go相关基因（HERG）通道：通过孔道残基Y652或F656突变减弱阻滞作用。

Naunyn Schmiedebergs Arch Pharmacol. 2007 Dec;376(4):275-84. doi: 10.1007/s00210-007-0202-6. Epub 2007 Oct 27.

2

Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.用于治疗帕金森病的药物的临床药代动力学和药效学特性。

Clin Pharmacokinet. 2002;41(4):261-309. doi: 10.2165/00003088-200241040-00003.

3

Difference between single and multiple dose pharmacokinetics of orphenadrine hydrochloride in man.

Eur J Clin Pharmacol. 1982;21(4):343-50. doi: 10.1007/BF00637624.

4

Clinical pharmacokinetics of anti-parkinsonian drugs.抗帕金森病药物的临床药代动力学

Clin Pharmacokinet. 1987 Sep;13(3):141-78. doi: 10.2165/00003088-198713030-00002.